Table 2.
Factors associated with overall survival in FIGO 2009 stage IIIB cervical cancer in Botswana: univariate and multivariable analyses (n=187)
| Factor | N | Overall survival, UVA (HR (95% CI)) | P value | Overall survival, MVA (HR (95% CI)) | P value |
|---|---|---|---|---|---|
| Age (≥50 years) | 89 | 1.04 (0.71 to 1.53) | 0.85 | 1.23 (0.72 to 2.07) | 0.449 |
| HIV status (seropositive) | 118 | 1.14 (0.76 to 1.70) | 0.53 | 1.50 (0.88 to 2.57) | 0.138 |
| Weight (kg) (≥60)* | 81 | 0.69 (0.45 to 1.06) | 0.09 | ||
| Body mass index (kg/m2) (≤20)* | 42 | 1.13 (0.70 to 1.83) | 0.61 | ||
| Tumor histology (SCC vs non-SCC) | 165 | 0.99 (0.55 to 1.82) | 0.99 | ||
| History of tuberculosis (yes) | 17 | 0.84 (0.41 to 1.73) | 0.63 | ||
| CD4 count (<400)* | 62 | 1.52 (0.91 to 2.55) | 0.11 | ||
| Viral load (≥400)* | 11 | 1.24 (0.56 to 2.74) | 0.60 | ||
| Hemoglobin (g/dL) (<12)* | 139 | 1.35 (0.79 to 2.31) | 0.28 | 1.10 (0.61 to 1.96) | 0.759 |
| Creatinine (μmol/L) (>90)* | 31 | 1.45 (0.89 to 2.38) | 0.14 | ||
| KPS (40–80 vs 90–100)* | 54 | 1.33 (0.88 to 2.01) | 0.18 | 1.27 (0.81 to 1.96) | 0.294 |
| ART (yes) | 110 | 1.41 (0.51 to 3.87) | 0.51 | ||
| Treatment | |||||
| Total RT dose, EQD2 (≥80 Gy) | 65 | 0.52 (0.34 to 0.82) | 0.04 | 0.57 (0.35 to 0.92) | 0.023 |
| Brachytherapy (yes)* | 120 | 0.42 (0.28 to 0.62) | <0.01 | ||
| CRT (yes) | 90 | 0.57 (0.38 to 0.85) | 0.01 | 0.63 (0.39 to 0.99) | 0.045 |
| Treatment response (complete)*† | 80 | 0.45 (0.29 to 0.70) | <0.01 | ||
| Treatment year (2013–15 vs 2016–18) | 73 | 0.85 (0.57 to 1.27) | 0.43 | ||
| TTT (>3 months)*‡ | 90 | 1.16 (0.73 to 1.84) | 0.54 | ||
| RT course length (<7 weeks)* | 106 | 0.91 (0.62 to 1.35) | 0.642 |
*
Data are incomplete due to missing individual patient data.
†
Treatment response is defined as clinically apparent tumor regression on examination.
‡
TTT is defined as time from pathological diagnosis to initiation of treatment.
ART, antiretroviral therapy; CRT, chemoradiation therapy; EQD2, radiobiological equivalent dose; FIGO, International Federation of Gynecology and Obstetrics; HIV, human immunodeficiency virus; KPS, Karnofsky Performance Score; MVA, multivariable analysis; RT, radiation therapy; SCC, squamous cell carcinoma; UVA, univariate multivariable analysis.